Abstract
A series of naphthalene diimide (ND)-based mono-, bis-, and tris-intercalators are synthesized and evaluated for their anticancer activities. All compounds show anticancer activities in the micromolar range. Among them the bis-intercalator is the most promising. Experimental results indicate that (i) target compounds intercalate DNA and (ii) the bis-intercalator with the optimal linker shows considerably more affinity to DNA than corresponding mono-and tris-intercalators. Spectroscopic measurements indicate that the ND groups bind to the double-stranded DNA (ds-DNA) in a classical threading intercalation mode, while the cationic linker reinforces the intercalation via electrostatic interaction with ds-DNA. In vitro cytotoxicity of the bis-intercalator towards a number of cancer cells, such as C6, HeLa, and MDA-435S, is tested and compared to that of normal cells. Attractive anticancer activity is observed with the bisintercalator, which provides a new lead in the anticancer drug design strategy.
Keywords: Anticancer, Bis-intercalator, C6 cell, Cancer, Circular dichroism spectroscopy, Cytotoxicity, DNA, Fluorometry, Hela cell, Intercalator, MDA-435S cell, Naphthalene diimide, Threading intercalation, UV-Vis spectrometry, Viscometry
Anti-Cancer Agents in Medicinal Chemistry
Title:Synthesis and Anticancer Properties of a Novel Bis-intercalator
Volume: 13 Issue: 4
Author(s): Wei Shen, Huimin Deng and Zhiqiang Gao
Affiliation:
Keywords: Anticancer, Bis-intercalator, C6 cell, Cancer, Circular dichroism spectroscopy, Cytotoxicity, DNA, Fluorometry, Hela cell, Intercalator, MDA-435S cell, Naphthalene diimide, Threading intercalation, UV-Vis spectrometry, Viscometry
Abstract: A series of naphthalene diimide (ND)-based mono-, bis-, and tris-intercalators are synthesized and evaluated for their anticancer activities. All compounds show anticancer activities in the micromolar range. Among them the bis-intercalator is the most promising. Experimental results indicate that (i) target compounds intercalate DNA and (ii) the bis-intercalator with the optimal linker shows considerably more affinity to DNA than corresponding mono-and tris-intercalators. Spectroscopic measurements indicate that the ND groups bind to the double-stranded DNA (ds-DNA) in a classical threading intercalation mode, while the cationic linker reinforces the intercalation via electrostatic interaction with ds-DNA. In vitro cytotoxicity of the bis-intercalator towards a number of cancer cells, such as C6, HeLa, and MDA-435S, is tested and compared to that of normal cells. Attractive anticancer activity is observed with the bisintercalator, which provides a new lead in the anticancer drug design strategy.
Export Options
About this article
Cite this article as:
Shen Wei, Deng Huimin and Gao Zhiqiang, Synthesis and Anticancer Properties of a Novel Bis-intercalator, Anti-Cancer Agents in Medicinal Chemistry 2013; 13 (4) . https://dx.doi.org/10.2174/1871520611313040011
DOI https://dx.doi.org/10.2174/1871520611313040011 |
Print ISSN 1871-5206 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5992 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Antitumor Activity of Benzamide Riboside In Vitro and In Vivo
Current Medicinal Chemistry Multi-Pharmacophore Modeling of Caspase-3 Inhibitors using Crystal, Dock and Flexible Conformation Schemes
Combinatorial Chemistry & High Throughput Screening EphA2 Receptor Tyrosine Kinase as a Promising Target for Cancer Therapeutics
Current Cancer Drug Targets Aim for the Readers! Bromodomains As New Targets Against Chagas’ Disease
Current Medicinal Chemistry Multimerization Improves Targeting of Peptide Radio-Pharmaceuticals
Current Pharmaceutical Design Methylenetetrahydrofolate Reductase: Biochemical Characterization and Medical Significance
Current Pharmaceutical Design Systematic Review on Infusion Reactions Associated with Chemotherapies and Monoclonal Antibodies for Metastatic Colorectal Cancer
Current Clinical Pharmacology CREG: A Possible Candidate for Both Prevention and Treatment of Proliferative Vascular Disease
Current Molecular Medicine Effects of Antioxidant Polyphenols on TNF-Alpha-Related Diseases
Current Topics in Medicinal Chemistry Targeting Protein Multiple Conformations: A Structure-Based Strategy for Kinase Drug Design
Current Topics in Medicinal Chemistry The Role of Insulin-Like Growth Factor I Components in the Regulation of Vitamin D
Current Pharmaceutical Biotechnology Nutraceuticals for Promoting Longevity
Current Nutraceuticals Can Targeting the Incretin Pathway Dampen RAGE-Mediated Events in Diabetic Nephropathy?
Current Drug Targets Development of Long-Circulating and Fusogenic Liposomes Co-encapsulating Paclitaxel and Doxorubicin in Synergistic Ratio for the Treatment of Breast Cancer
Current Drug Delivery Editorial (Hot Topic: Natural Products as Anti-Cancer Agents: Understanding their Mechanism of Action)
Current Drug Targets Protein Secretome Analysis of Evolving and Responding Tumor Ecosystems
Current Proteomics Nose to Brain Delivery of Nanoformulations for Neurotherapeutics in Parkinson’s Disease: Defining the Preclinical, Clinical and Toxicity Issues
Current Drug Delivery 6-Membered Pyrrololactams: An Overview of Current Synthetic Approaches to their Preparation
Current Organic Chemistry Recombinant Antibodies in Cancer Therapy
Current Protein & Peptide Science Profile of HBV Integration in the Plasma DNA of Hepatocellular Carcinoma Patients
Current Genomics